ReviewJournal of inflammation research2018
Fecal microbiota transplant - a new frontier in inflammatory bowel disease.
Review in Journal of inflammation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Fecal microbiota transplantation for the treatment of intestinal and extra-intestinal diseases: Mechanism basis, clinical application, and potential prospect.Bioengineering & translational medicine · 2025Review
- Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy.Therapeutic advances in gastroenterology · 2025Review
- Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.Inflammatory bowel diseases · 2024Review
- Review
- Therapeutic Perspectives for Microbiota Transplantation in Digestive Diseases and Neoplasia-A Literature Review.Pathogens (Basel, Switzerland) · 2023Review
- Inflammatory bowel disease andTherapeutic advances in gastroenterology · 2023Review
- Current Trends and Challenges of Fecal Microbiota Transplantation-An Easy Method That Works for All?Biomedicines · 2022Review
- Review of Literature onJournal of the ASEAN Federation of Endocrine Societies · 2022Review
- Investigating dysbiosis and microbial treatment strategies in inflammatory bowel disease based on two modified Koch's postulates.Frontiers in medicine · 2022Review
- The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.Frontiers in immunology · 2022Review
- Orally Administered Natural Lipid Nanoparticle-Loaded 6-Shogaol Shapes the Anti-Inflammatory Microbiota and Metabolome.Pharmaceutics · 2021Article
- Age-related changes in intestinal immunity and the microbiome.Journal of leukocyte biology · 2021Review
- The link among microbiota, epigenetics, and disease development.Environmental science and pollution research international · 2021Review
- Prevalence of an Intestinal ST40International journal of molecular sciences · 2020Article
- Galangin Protects against Symptoms of Dextran Sodium Sulfate-induced Acute Colitis by Activating Autophagy and Modulating the Gut Microbiota.Nutrients · 2020Article
- Fecal microbiota transplantation results in bacterial strain displacement in patients with inflammatory bowel diseases.FEBS open bio · 2020Article
- Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases.Frontiers in bioengineering and biotechnology · 2020Review
- Metabolic Profiling by UPLC-Orbitrap-MS/MS of Liver from C57BL/6 Mice with DSS-Induced Inflammatory Bowel Disease.Mediators of inflammation · 2020Article
- Microbiota, Microbial Metabolites, and Barrier Function in A Patient with Anorexia Nervosa after Fecal Microbiota Transplantation.Microorganisms · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic multifactorial disease that affects the gastrointestinal tract and results from an aberrant immune response toward luminal antigens in genetically susceptible people. Most of the current therapies for IBD focus on the management of the inflammation by using corticosteroids, immune modulators, and more recently, monoclonal antibodies (biological therapy). Although these therapies provide benefit in most cases, there are still a significant number of patients who do not respond or become refractory over time, suggesting the need for alternative therapeutic options. In the last decade, it has been recognized that "dysbiosis," an imbalanced gut microbiota, is a key element in IBD suggesting microbiome-based therapies as an attractive approach. Recently, fecal microbiota transplant (FMT) has been successfully used for the treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.